## First-Line Endocrine Therapy in Metastatic HR+ Breast Cancer **Key Point:** In postmenopausal women with HR+ metastatic breast cancer who have not received prior endocrine therapy, aromatase inhibitors (AIs) are the preferred first-line agents. ### Rationale for Aromatase Inhibitors **High-Yield:** Aromatase inhibitors (letrozole, anastrozole, exemestane) are superior to tamoxifen in postmenopausal women because they: - Block peripheral conversion of androgens to estrogen via aromatase enzyme - Achieve lower circulating estrogen levels (~97% reduction) - Demonstrate superior progression-free survival and response rates compared to tamoxifen in this population [cite:Harrison 21e Ch 352] ### Comparative Table: First-Line Endocrine Agents | Agent | Population | Mechanism | Status | | --- | --- | --- | --- | | **Aromatase Inhibitor** | Postmenopausal | Blocks estrogen synthesis | **First-line** | | Tamoxifen | Pre- or postmenopausal | ER antagonist | Second-line postmenopausal; first-line premenopausal | | Fulvestrant | Any | ER degrader | Second-line (after AI progression) | | Trastuzumab | HER2+ only | Anti-HER2 monoclonal Ab | Not indicated (patient is HER2−) | **Clinical Pearl:** Aromatase inhibitors are ineffective in premenopausal women unless combined with ovarian suppression (GnRH agonist), because ovarian estrogen production bypasses the aromatase block. ### Treatment Sequence 1. **First-line:** AI (letrozole or anastrozole) ± CDK4/6 inhibitor (palbociclib, ribociclib) for improved PFS 2. **Second-line (on progression):** Fulvestrant or switch to different AI 3. **Third-line:** Fulvestrant + CDK4/6 inhibitor or mTOR inhibitor (everolimus) **Tip:** The addition of CDK4/6 inhibitors to first-line AI has become standard in many centers, significantly improving progression-free survival.
Sign up free to access AI-powered MCQ practice with detailed explanations and adaptive learning.